dc.creatorMATTSSON, Niklas
dc.creatorANDREASSON, Ulf
dc.creatorPERSSON, Staffan
dc.creatorARAI, Hiroyuki
dc.creatorBATISH, Sat Dev
dc.creatorBERNARDINI, Sergio
dc.creatorBOCCHIO-CHIAVETTO, Luisella
dc.creatorBLANKENSTEIN, Marinus A.
dc.creatorCARRILLO, Maria C.
dc.creatorCHALBOT, Sonia
dc.creatorCOART, Els
dc.creatorCHIASSERINI, Davide
dc.creatorCUTLER, Neal
dc.creatorDAHLFORS, Gunilla
dc.creatorDULLER, Stefan
dc.creatorFAGAN, Anne M.
dc.creatorFORLENZA, Orestes
dc.creatorFRISONI, Giovanni B.
dc.creatorGALASKO, Douglas
dc.creatorGALIMBERTI, Daniela
dc.creatorHAMPEL, Harald
dc.creatorHANDBERG, Aase
dc.creatorHENEKA, Michael T.
dc.creatorHERSKOVITS, Adrianna Z.
dc.creatorHERUKKA, Sanna-Kaisa
dc.creatorHOLTZMAN, David M.
dc.creatorHUMPEL, Christian
dc.creatorHYMAN, Bradley T.
dc.creatorIQBAL, Khalid
dc.creatorJUCKER, Mathias
dc.creatorKAESER, Stephan A.
dc.creatorKAISER, Elmar
dc.creatorKAPAKI, Elisabeth
dc.creatorKIDD, Daniel
dc.creatorKLIVENYI, Peter
dc.creatorKNUDSEN, Cindy S.
dc.creatorKUMMER, Markus P.
dc.creatorLUI, James
dc.creatorLLADO, Albert
dc.creatorLEWCZUK, Piotr
dc.creatorLI, Qiao-Xin
dc.creatorMARTINS, Ralph
dc.creatorMASTERS, Colin
dc.creatorMCAULIFFE, John
dc.creatorMERCKEN, Marc
dc.creatorMOGHEKAR, Abhay
dc.creatorMOLINUEVO, Jose Luis
dc.creatorMONTINE, Thomas J.
dc.creatorNOWATZKE, William
dc.creatorO`BRIEN, Richard
dc.creatorOTTO, Markus
dc.creatorPARASKEVAS, George P.
dc.creatorPARNETTI, Lucilla
dc.creatorPETERSEN, Ronald C.
dc.creatorPRVULOVIC, David
dc.creatorREUS, Herman P. M. de
dc.creatorRISSMAN, Robert A.
dc.creatorSCARPINI, Elio
dc.creatorSTEFANI, Alessandro
dc.creatorSOININEN, Hilkka
dc.creatorSCHROEDER, Johannes
dc.creatorSHAW, Leslie M.
dc.creatorSKINNINGSRUD, Anders
dc.creatorSKROGSTAD, Brith
dc.creatorSPREER, Annette
dc.creatorTALIB, Leda
dc.creatorTEUNISSEN, Charlotte
dc.creatorTROJANOWSKI, John Q.
dc.creatorTUMANI, Hayrettin
dc.creatorUMEK, Robert M.
dc.creatorBROECK, Bianca Van
dc.creatorVANDERSTICHELE, Hugo
dc.creatorVECSEI, Laszlo
dc.creatorVERBEEK, Marcel M.
dc.creatorWINDISCH, Manfred
dc.creatorZHANG, Jing
dc.creatorZETTERBERG, Henrik
dc.creatorBLENNOW, Kaj
dc.date.accessioned2012-10-19T17:35:18Z
dc.date.accessioned2018-07-04T15:09:11Z
dc.date.available2012-10-19T17:35:18Z
dc.date.available2018-07-04T15:09:11Z
dc.date.created2012-10-19T17:35:18Z
dc.date.issued2011
dc.identifierALZHEIMERS & DEMENTIA, v.7, n.4, p.386-395, 2011
dc.identifier1552-5260
dc.identifierhttp://producao.usp.br/handle/BDPI/22520
dc.identifier10.1016/j.jalz.2011.05.2243
dc.identifierhttp://dx.doi.org/10.1016/j.jalz.2011.05.2243
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1619292
dc.description.abstractBackground: The cerebrospinal fluid (CSF) biomarkers amyloid beta (A beta)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer`s disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer`s Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program. Methods: The program is open for laboratories using commercially available kits for A beta, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Molndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples. Results: Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure A beta-(1-42), P-tau(181P), and T-tau), and 5 used Mesa Scale Discovery with the A beta triplex (A beta N-42, A beta N-40, and A beta N-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories. Conclusions: Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers. (C) 2011 The Alzheimer`s Association. All rights reserved.
dc.languageeng
dc.publisherELSEVIER SCIENCE INC
dc.relationAlzheimers & Dementia
dc.rightsCopyright ELSEVIER SCIENCE INC
dc.rightsrestrictedAccess
dc.subjectAlzheimer`s disease
dc.subjectCerebrospinal fluid
dc.subjectBiomarkers
dc.subjectExternal assurance
dc.subjectExternal control
dc.subjectProficiency testing
dc.titleThe Alzheimer`s Association external quality control program for cerebrospinal fluid biomarkers
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución